CDKL2, cyclin dependent kinase like 2, 8999

N. diseases: 20; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007621
Disease: Neoplastic Cell Transformation
Neoplastic Cell Transformation
0.300 Biomarker phenotype CTD_human CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. 25333262 2014
CUI: C0024668
Disease: Mammary Neoplasms, Experimental
Mammary Neoplasms, Experimental
0.300 Biomarker phenotype CTD_human CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. 25333262 2014
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.300 Biomarker phenotype CTD_human Furthermore, CDKL2 enhanced primary tumor formation and metastasis in a breast cancer xenograft model. 25333262 2014
CUI: C0235874
Disease: Disease Exacerbation
Disease Exacerbation
0.300 Biomarker phenotype CTD_human CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. 25333262 2014
CUI: C1335167
Disease: Ovarian Mucinous Adenocarcinoma
Ovarian Mucinous Adenocarcinoma
0.300 GeneticVariation disease UNIPROT
CUI: C1336708
Disease: Testicular Germ Cell Tumor
Testicular Germ Cell Tumor
0.100 GeneticVariation disease GWASCAT Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. 28604728 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 AlteredExpression group BEFREE Furthermore, the methylation of CDKL2 was negatively correlated with its mRNA expression (p < 0.001, r<sub>s</sub> = -0.513), and was associated with gender (p = 0.023), age (p = 0.001) and tumor size (p = 0.016). 30292871 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.020 GeneticVariation group BEFREE Analyses by early age at diagnosis and by estrogen receptor α (ERα) tumor status indicated potential associations for rs6852678 in CDKL2 (OR = 0.32, 95% CI: 0.10-1.00; P(recessive) = 0.044) and rs10878640 in DYRK2 (OR = 2.39, 95% CI: 1.32-4.30; P(dominant) = 0.003), and for rs12765929, rs9836340, rs4707795 in BMPR1A, EPHA3 and EPHA7, respectively (ERα tumor status P(interaction)<0.05). 21124932 2010
CUI: C0009241
Disease: Cognition Disorders
Cognition Disorders
0.010 Biomarker group BEFREE Treatment with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), a potent sEH inhibitor, in juvenile offspring from prenatal day (P) 28 to P56 could prevent cognitive deficits and loss of parvalbumin (PV) immunoreactivity in the medial PFC of adult offspring after MIA. 30890645 2019
CUI: C0038220
Disease: Status Epilepticus
Status Epilepticus
0.010 GeneticVariation disease BEFREE Male rats underwent pilocarpine-induced status epilepticus (SE) or sham treatment at P56. 31270158 2019
CUI: C0338656
Disease: Impaired cognition
Impaired cognition
0.010 Biomarker disease BEFREE Treatment with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), a potent sEH inhibitor, in juvenile offspring from prenatal day (P) 28 to P56 could prevent cognitive deficits and loss of parvalbumin (PV) immunoreactivity in the medial PFC of adult offspring after MIA. 30890645 2019
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis
0.010 Biomarker disease BEFREE Our results showed that CDKL2 promoter hypermethylation played an important role in hepatocarcinogenesis and might be a valuable biomarker for HCC diagnosis. 30292871 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.010 AlteredExpression disease BEFREE Additionally, the mRNA expression levels of CDKL2 were decreased both in HCC tissues and cell lines than those in normal liver tissues (All p < 0.05), and the expression could be upregulated by 5-aza-2'-deoxycytidine treatment in HCC cell lines. 30292871 2019
CUI: C0001339
Disease: Acute pancreatitis
Acute pancreatitis
0.010 Biomarker disease BEFREE Effects of ω-3 Fatty Acids on Toll-like Receptor 4 and Nuclear Factor κB p56 in the Pancreas of Rats With Severe Acute Pancreatitis. 28984787 2018
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.010 Biomarker disease BEFREE Thus, we conducted this study to explore the clinical effect of CDKL2 in GC. 29790675 2018
CUI: C0424295
Disease: Hyperactive behavior
Hyperactive behavior
0.010 GeneticVariation phenotype BEFREE These local hyper-methylated patterns are highly consistent: 84 sites (from 61 promoters) are hyper-methylated in all the three studied data sets, including many previously reported genes, such as CDKL2, TBX15 and NKX6-2. 27760737 2018
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.010 Biomarker disease BEFREE Thus, we conducted this study to explore the clinical effect of CDKL2 in GC. 29790675 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 AlteredExpression phenotype BEFREE Cellular studies revealed that CDKL2 overexpression impaired cell proliferation and invasion. 29790675 2018
CUI: C0027092
Disease: Myopia
Myopia
0.010 Biomarker disease BEFREE Compared with WT littermates, the A2AR KO mice displayed relative myopia (average difference, 5.1 D between P28 and P35) and associated increases in VC depth and axial length from P28 to P56. 20484596 2010
CUI: C0206633
Disease: Angiomyolipoma
Angiomyolipoma
0.010 Biomarker disease BEFREE Tuberin (TSC2) was weak or absent in angiomyolipomas, but present in healthy kidney, whereas, phosphorylated p70 S6 kinase and p56 were present only in angiomyolipomas. 12711473 2003
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma
0.010 Biomarker disease BEFREE We detected transcripts initiating from both the P105 and the P56 in primary keratinocytes harboring episomal HPV18 as well as in the HPV 18 positive cervical carcinoma cell lines HeLa, C4-1 and SW756. 11765912 2001